Endoscopic sinus surgery (ESS) markedly improves patients’ quality of life in recurrent acute rhinosinusitis (RARS) compared with conservative medical therapy.
The randomized clinical trial showed a significant reduction in symptom burden as measured by the SinoNasal Outcome Test 22 (SNOT-22) at 6-month follow-up.
ESS demonstrated a favorable safety profile, with only a small number of manageable operative complications.
Conservative management alone failed to achieve clinically meaningful improvements in this patient population.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
